Where Can I Get More Information?

- Call the Research Department at St. Peter’s Cancer Care Center at (518) 525-6739
- Visit St. Peter’s website at www.sphcs.org
- Call the NCI’s Cancer Center Information service at 1-800-4-CANCER (1-800-422-6237)
- Visit NCI’s website at www.cancer.gov or the ACOSOG website at www.acosog.org

Dr. Jason T. Heckman

**HEPATO-PANCREATICO-BILIARY SURGERY PRINCIPAL INVESTIGATOR, CLINICAL STUDY**

A specialist in liver, pancreas, general and advanced laparoscopic surgery, Jason T. Heckman, M.D., has been trained in cutting-edge techniques to perform minimally invasive liver and pancreas surgery. He is a graduate of the University of Rochester School of Medicine & Dentistry in Rochester, NY.

Dr. Rebecca L. Keim

**HEPATO-PANCREATICO-BILIARY SURGERY PRINCIPAL INVESTIGATOR, CLINICAL STUDY**

A graduate of The Medical College of Wisconsin in Milwaukee, WI, Dr. Keim is a specialist in liver, pancreas, general and advanced laparoscopic surgery. She has been trained in cutting-edge techniques to perform minimally invasive liver and pancreas surgery.

Dr. Arthur L. Sunkin

**MEDICAL ONCOLOGIST / HEMATOLOGIST ST. PETER’S CANCER CARE CENTER PRINCIPAL INVESTIGATOR, CLINICAL STUDY**

Board-certified in Internal Medicine and Medical Oncology, Arthur L. Sunkin, M.D., is Chief of the Medical Oncology/Hematology Practice in St. Peter’s Cancer Care Center. He is a graduate of George Washington University and George Washington University Medical Center.

**ST. PETER’S CANCER CARE CENTER**

317 South Manning Boulevard

Albany, NY 12208

518-525-6739

www.sphcs.org

**A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma**

Advanced treatment options, dedicated professionals and a unique caring environment make St. Peter’s one of the most well-regarded health systems.

In recent years, St. Peter’s Hospital has been recognized by national and state health care quality organizations for excellence in care. We offer a comprehensive, integrated continuum of services – ranging from acute care in the hospital to outpatient services, home care, nursing homes, hospice care, addictions treatment and much more.

St. Peter’s continues to set the pace for health care innovations. We are 4,500 professionals who know that technology is critical to treatment, but compassion is the key to healing.
If you are having surgery for pancreatic cancer, you may be able to participate in a new clinical study.

Z5041: A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma

What Is A Clinical Study?
Clinical studies (or “trials”) are a type of research involving patient volunteers. They are designed to find better ways to treat disease.

What Type Of Study Is This?
This study is a clinical trial for patients who are going to have surgery for pancreatic cancer. This study is looking at chemotherapy before and after surgery as a new treatment option.

Who Can Participate In This Study?
You can participate in this study if:
• You have cancer in the head of the pancreas that is considered removable with surgery
• Your cancer has not spread to other organs
• You have not received any treatment for your pancreatic cancer

Why Is This Study Being Done?
The purpose of this study is to find out whether a combination of chemotherapy drugs, given to you before surgery, can help to increase the likelihood of your surgeon removing your pancreatic tumor.

This study is also designed to examine whether the same chemotherapy can be given safely after surgery to reduce the chances of your cancer returning. These drugs are FDA-approved for treatment of advanced pancreatic cancer, but use of these drugs to treat tumors that are removable by surgery is considered experimental. The drugs are called gemcitabine and erlotinib.

This study is also intended to answer questions about how chemotherapy affects pancreatic tumors and which tumors respond to this form of treatment. This is done using samples of blood and tumor tissue taken at biopsy and surgery. For this reason your consent will be requested for access to blood samples and tumor samples.

Who Is Conducting This Study?
This study is being conducted by the American College of Surgeons Oncology Group (ACOSOG). ACOSOG is a research group funded by the National Cancer Institute (NCI).

What Is Involved In This Study?
If you decide to participate in this study, you will read and sign a consent form that explains the study in more detail. If you meet all of the study requirements, you will then be entered into the study.

What Are the Costs Of This Study?
There are no extra costs for this study. The erlotinib and study-related tests will be paid for by the study. You or your insurance company will be responsible for the costs of the surgery that would be done even if you were not part of this study.

What Will I Have To Do During The Study?
If you choose to participate in this study, you will have some tests done. The tests include:
• Health history and physical exam
• Laboratory studies and blood tests
• CT scans and x-rays
• Pancreas biopsy
You also will complete a questionnaire about your smoking history, because smoking can affect the amount of erlotinib in the bloodstream. You will have chemotherapy at the hospital or at your doctor’s office. You will undergo surgery to remove the tumor. You will have the same chemotherapy after surgery. After treatment, you will be asked to visit your doctor every few months.

What Are The Benefits Of Being In This Study?
Doctors hope that erlotinib and gemcitabine will be more effective than the standard treatment for pancreatic cancer. This study will help doctors learn more about the use of this combination of chemotherapy as a treatment for cancer. This information could help future cancer patients.

Are There Possible Side Effects?
You may experience side effects while in this study. Your doctor or nurse will explain them to you.

Am I Required To Be In This Study?
No. Taking part in this study is voluntary. You are free to choose to participate, not to participate, or to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.

How Do I Participate?
If you are interested in this study, please speak to your doctor and the members of your health care team to discuss the possible benefits and risks of participating. You should feel free to discuss this brochure and this study with your family and friends.